2Q EARNINGS: Bristol-Myers lowers profit forecast as sales sink
This article was originally published in Scrip
Bristol-Myers Squibb lowered its profit forecast for the year, citing declining sales as the company continues to struggle to replace lost revenue following patent expirations. As expected, the company reported quarterly profit dropped.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.